AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 262 min read$UTHR

ROTHBLATT MARTINE A sold $5.2M of UTHR

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $550.40 ($543.54–$554.84, $5.23M total) across 11 trades on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Jun 26, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Neutral
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

The newest concrete information is the disclosed open-market sale size ($5.23M), share count (9,500 across 11 trades), and the stated use of a pre-arranged 10b5-1 plan.

02

Market read

This provides a fresh, timestamped insider-selling datapoint for UTHR, but it lacks any new operational or financial guidance catalyst.

03

What to watch

Traders may over-weight insider sales; without accompanying buys, guidance changes, or operational news, the signal is typically weaker—watch for subsequent filings (additional sales/buys) and next fundamental catalysts.

Relevance 5/10Novelty 5/10Timing: after-hours/filing date (2026-06-26) for a 2026-06-25 insider sale

Background

The article is an SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR) by CEO/Chair Martine Rothblatt.

Company-level read

Ticker impact

$UTHRNeutralMedium confidence
Context

United Therapeutics Form 4 shows CEO/Chair Martine Rothblatt sold $5.23M of UTHR shares via an open-market transaction under a 10b5-1 plan on 2026-06-25.

Expected impact

Likely limited, short-lived sentiment impact; follow-through depends on broader tape/earnings context rather than this filing alone.

Evidence & confidence

The filing is primary-source and time-stamped, but it specifies a pre-arranged 10b5-1 plan and provides no new company fundamentals (no guidance, trial, deal, or regulatory action).

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

Regional

Minimal; no macro/regional linkage is provided beyond the US-listed issuer.

Global

Minimal; no international transaction or regulatory action is mentioned.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity/portfolio management rather than bearish expectations.

Key entities

  • issuer
    United Therapeutics Corp

    Subject of the Form 4 insider transaction; CEO/Chair sold shares on 2026-06-25 under a 10b5-1 plan.

  • insider
    ROTHBLATT MARTINE A

    Chairperson & CEO who executed the open-market sale disclosed in the Form 4.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

SEP 10
$UTHRMed

Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?

United Therapeutics (UTHR) is under scrutiny after the FDA accepted its supplemental New Drug Application for Tyvaso in idiopathic pulmonary fibrosis. The company's stock has seen short-term declines, but long-term returns remain strong. Analysts suggest UTHR may be undervalued, with a fair value estimate of $665.23, citing its drug pipeline and innovation. However, risks include potential trial disappointments and competition.

simplywall.st2 min
SEP 9
$UTHRMed

United Therapeutics at Cantor healthcare conference: fibrosis push widens

United Therapeutics (UTHR) announced a strategic shift toward pulmonary fibrosis at the Cantor Fitzgerald Global Healthcare Conference, aiming for a 10-fold market expansion. The company presented strong clinical data for nebulized Tyvaso, with FDA review expected by April 2027. Management also announced a $500M stock repurchase and plans for 14 product launches through 2029, including new Tyvaso formulations and ralinepag products. The company projects a significant revenue opportunity in the p

investing.com3 min
SEP 9
$UTHRMedAI 8/10

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

United Therapeutics (UTHR) stock rose 4.3% post-earnings, trading at $214.36. Myriad Genetics (MYGN) reported $190.7M revenue, down 10.5% YoY, missing estimates, and guidance fell short, causing a 40.9% stock drop to $3.18. Gilead Sciences (GILD) reported $7.8B revenue, up 10.2% YoY, beating estimates, with stock up 8.1% to $146.16. Novavax (NVAX) reported $56.7M revenue, down 76.3% YoY, but beat estimates, with stock up 32.2% to $10.18.

finance.yahoo.com3 min